Cite
MLA Citation
Bruce E Sands et al.. “Ustekinumab versus adalimumab for induction and maintenance therapy in biologic-naive patients with moderately to severely active Crohn's disease: a multicentre, randomised, double-blind, parallel-group, phase 3b trial.” Lancet, vol. 399, no. 10342, 2022, pp. 2200–2211. http://access.bl.uk/ark:/81055/vdc_100156692342.0x00004e